Early on in the development of the Ebola Vaccines, shortly after the virus was identified, the main focus was on strategies to render the virus inactive. Since then, progress has been made in the preclinical development of a wide range of various platforms, including DNA vaccines, recombinant viral vectors, recombinant proteins, subunit proteins, and VLPs. When effectiveness in preclinical animals or promising immunogenicity at potentially protective levels is discovered, Ebola Vaccines are often proceeded to clinical development. In clinical trials, reactogenicity and immunogenicity of vaccines are assessed in order to determine the best dosages and delivery schedules for producing protective immunity in the target population. Eight vaccines are now undergoing clinical testing; all of them target the GP of the Ebola virus, but they differ in terms of the predominate immune response they generate, how the antigen is administered, and how reactogenic the vaccines are.
Read More- https://cmiblogdailydose.blogspot.com/2023/03/several-ebola-vaccines-are-being-tested.html
